Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY900027 vs Insulin Lispro in T1DM on Pump Therapy
NCT04161976Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro-aabc in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Insulin Lispro Curve (AUC) 0 to 5 hours and Maximum Observed Insulin Lispro Concentration at Day 10. Started Dec 2019; status: completed.
02
Drugs
insulin lispro-aabc
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04161976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161976.